Effectiveness and Safety of Vedolizumab in Anti-TNF-Naïve Patients With Inflammatory Bowel Disease-A Multicenter Retrospective European Study.

Background Vedolizumab (VDZ) is effective for treatment of ulcerative colitis (UC) and Crohn's disease (CD). In GEMINI trials, anti-tumor necrosis factor (anti-TNF)-naïve patients had a superior response compared with anti-TNF-exposed patients. In real-world experience (RWE), the number of included anti-TNF-naïve patients was low. We aimed to evaluate the effectiveness and safety of VDZ in anti-TNF-naïve patients in an RWE setting. Methods This retrospective multicenter European pooled cohort study included consecutive active anti-TNF-naïve IBD patients treated with VDZ. The primary end point was clinical response at week 14. Patients with follow-up beyond week 14 and those discontinuing VDZ at any time were included for maintenance outcomes analysis. Results Since January 2015, 184 anti-TNF-naïve patients from 23 centers initiated VDZ treatment (Crohn's disease [CD], 50; ulcerative colitis [UC], 134). In CD, 42/50 (82%) patients responded by week 14 and 32 (64%) were in clinical remission; 26/50 (52%) achieved corticosteroid-free remission (CSFR). At last follow-up (44 weeks; interquartile range [IQR], 30-52 weeks), 27/35 (77.1%) patients with available data responded to treatment; 24/35 (68.6%) were in clinical remission, 21/35 (60%) were in CSFR. For UC, 116/134 (79.1%) responded to treatment by week 14, including 53 (39.5%) in clinical remission; 49/134 (36.6%) achieved CSFR. At last follow-up (42.5 weeks; IQR, 30-52 weeks), 79/103 (76.7%) patients responded to treatment, 69/103 (67.0%) were in remission, and 61/103 (59.2%) were in CSFR. Adverse effects were reported in 20 (11%) of the patients, leading to treatment discontinuation in 6 (3.3%). Conclusions VDZ is similarly effective in ant-TNF-naïve CD and UC patients. The efficacy is higher than reported in anti-TNF-experienced patients and is comparable to that of anti-TNF biologics in this population.

[1]  U. Kopylov,et al.  Vedolizumab in IBD–Lessons From Real-world Experience; A Systematic Review and Pooled Analysis , 2018, Journal of Crohn's & colitis.

[2]  B. Flourié,et al.  Association Between Low Trough Levels of Vedolizumab During Induction Therapy for Inflammatory Bowel Diseases and Need for Additional Doses Within 6 Months , 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[3]  B. Feagan,et al.  Vedolizumab Demonstrates Early Symptomatic Improvement in Ulcerative Colitis: A GEMINI 1 Post hoc Analysis: 670 , 2017 .

[4]  J. Gisbert,et al.  Clinical Outcomes of Golimumab as First, Second or Third Anti-TNF Agent in Patients with Moderate-to-Severe Ulcerative Colitis , 2017, Inflammatory bowel diseases.

[5]  J. Gisbert,et al.  Erratum to: Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naïve and non-naïve patients , 2017, Journal of Gastroenterology.

[6]  J. Ludvigsson,et al.  Long-term effectiveness of vedolizumab in inflammatory bowel disease: a national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG) , 2017, Scandinavian journal of gastroenterology.

[7]  A. Ananthakrishnan,et al.  Predictors of Clinical Response and Remission at 1 Year Among a Multicenter Cohort of Patients with Inflammatory Bowel Disease Treated with Vedolizumab , 2017, Digestive Diseases and Sciences.

[8]  R. Eliakim,et al.  Efficacy and Safety of Vedolizumab for Induction of Remission in Inflammatory Bowel Disease—the Israeli Real-World Experience , 2017, Inflammatory bowel diseases.

[9]  J. Andrews,et al.  Infliximab vs. adalimumab in Crohn's disease: results from 327 patients in an Australian and New Zealand observational cohort study , 2017, Alimentary pharmacology & therapeutics.

[10]  S. Vermeire,et al.  Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists , 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[11]  J. Hampe,et al.  Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease – a prospective multicenter observational study , 2016, Alimentary pharmacology & therapeutics.

[12]  A. Amiot,et al.  Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease. , 2016, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[13]  A. Kaser,et al.  Long-term Efficacy of Vedolizumab for Crohn’s Disease , 2016, Journal of Crohn's & colitis.

[14]  John T. Chang,et al.  The Real-World Effectiveness and Safety of Vedolizumab for Moderate–Severe Crohn’s Disease: Results From the US VICTORY Consortium , 2016, The American Journal of Gastroenterology.

[15]  S. Schreiber,et al.  Vedolizumab induction therapy for inflammatory bowel disease in clinical practice – a nationwide consecutive German cohort study , 2016, Alimentary pharmacology & therapeutics.

[16]  Chien-Huan Chen,et al.  Vedolizumab Effectiveness and Safety Over the First Year of Use in an IBD Clinical Practice. , 2016, Journal of Crohn's & colitis.

[17]  A. Ananthakrishnan,et al.  Efficacy of Vedolizumab as Induction Therapy in Refractory IBD Patients: A Multicenter Cohort , 2015, Inflammatory bowel diseases.

[18]  B. Bressler,et al.  Vedolizumab for ulcerative colitis and Crohn's disease: results and implications of GEMINI studies. , 2014, Immunotherapy.

[19]  J. Xu,et al.  Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. , 2014, Gastroenterology.

[20]  S. Ben-Horin,et al.  Tailoring anti-TNF therapy in IBD: drug levels and disease activity , 2014, Nature Reviews Gastroenterology &Hepatology.

[21]  Kristin Stephens,et al.  Vedolizumab as induction and maintenance therapy for Crohn's disease. , 2013, The New England journal of medicine.

[22]  C. J. J. Mulder,et al.  Adalimumab and infliximab are equally effective for Crohn's disease in patients not previously treated with anti-tumor necrosis factor-α agents. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[23]  J. Xu,et al.  Long-term Clinical Experience with Vedolizumab in Patients with Inflammatory Bowel Disease , 2013, Inflammatory bowel diseases.

[24]  P. Rutgeerts,et al.  The efficacy and safety of a third anti‐TNF monoclonal antibody in Crohn’s disease after failure of two other anti‐TNF antibodies , 2010, Alimentary pharmacology & therapeutics.

[25]  P. Rutgeerts,et al.  Mucosal healing predicts long‐term outcome of maintenance therapy with infliximab in Crohn's disease , 2009, Inflammatory bowel diseases.

[26]  K. Van Steen,et al.  Long-term outcome of treatment with infliximab in 614 patients with Crohn’s disease: results from a single-centre cohort , 2008, Gut.

[27]  K. Van Steen,et al.  Long-term outcome after infliximab for refractory ulcerative colitis. , 2008, Journal of Crohn's & colitis.

[28]  E. Brown,et al.  The Medical Dictionary for Regulatory Activities (MedDRA) , 1999, Drug safety.

[29]  B. Sands,et al.  Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy , 2017, Inflammatory bowel diseases.

[30]  P. Riis.  Therapeutic influence on the prognosis of ulcerative colitis. , 1974, Scandinavian journal of gastroenterology.